Clinical Trial Update: Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas [Phase 1]

View source ↗

Summary

Phase 1 study evaluating CADI-05 in combination with pembrolizumab for surgically resectable locally advanced head and neck squamous cell carcinoma, currently r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• CADI-05
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Fox Chase Cancer Center | Conditions: Squamous Cell Carcinoma of Head and Neck | Phase 1 | Status: RECRUITING